Project Grant R01CA315904
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $467K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $148,626 through the Cancer Research Manpower program (CFDA 93.398) to the University of Pennsylvania, effective December 1, 2025 through April 30, 2028. This Project Grant supports research training and workforce development focused on elucidating the role of N6-methyladenosine (m6A) modifications on messenger RNA (mRNA) during adaptive stress responses in prostate cancer. The research addresses a critical gap in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $518,151 Project Grant to the University of Chicago effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and preclinical advancement of NNMTI'960, a small-molecule inhibitor targeting Nicotinamide N-methyltransferase (NNMT) in the tumor microenvironment. The research investigates how NNMT inhibition reshapes tumor metabolism...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a $658,033 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026, through May 31, 2031. This award supports research focused on advancing cancer interception strategies to interrupt pancreatic ductal adenocarcinoma (PDAC) natural history in high-risk patients. The project addresses the critical clinical need to eliminate premalignant...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $658,423 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on therapeutic targeting of PI3K gamma-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC). The research aims to develop innovative therapeutics that reduce health disparities...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $459,902 to the University of Pennsylvania, effective August 1, 2025 through May 31, 2030, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award provides salary support for Dr. Charly Good, a research specialist conducting mechanistic investigations into how wildtype (WT) and gain-of-function (GOF) mutant p53 proteins regulate gene expression in cancer cells. Dr. Good's...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $477,674 Project Grant to The Johns Hopkins University, effective June 1, 2026 through May 31, 2031, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). This research initiative focuses on molecular imaging of the immune-suppressive tumor microenvironment (TME) in prostate cancer and its response to immune checkpoint inhibitor (CIT) therapy. The project will employ molecular and functional imaging...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of Massachusetts Medical School a Project Grant totaling $622,611 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with completion targeted for May 31, 2031. The research project, "Creating Cancer-Specific Genotoxicity by Targeting Cas9 Nickase to Focal Gene Amplifications," develops and evaluates a novel therapeutic approach using Cas9 nickase technology to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Pennsylvania a Project Grant totaling $434,969 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2031. This research grant supports investigation into the cellular mechanisms underlying FLT3 (Fms-like tyrosine kinase 3)-mutant clone persistence in acute myeloid leukemia (AML) during targeted therapy. The project employs genetically engineered mouse models with...